Innoviva Inc - Company Profile
Powered by 
All the sales intelligence you need on Innoviva Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Innoviva Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Innoviva Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Innoviva Inc (Innoviva) is a diversified biopharmaceutical company focused on investing in areas of high unmet medical need and developing differentiated therapies. Its major products include respiratory assets such as RELVAR or BREO ELLIPTA and ANORO ELLIPTA, and critical care and infectious disease therapeutics like GIAPREZA, XERAVA, and XACDURO. The company collaborates with other pharmaceutical companies for its respiratory products and has an exclusive distribution and license agreement for ZEVTERA in the US. The company relies on third-party manufacturers to produce its products and maintains confidentiality agreements to protect its proprietary rights. Its operations are based in the US. Innoviva is headquartered in Burlingame, California, the US.
Headquarters
United States of America
Address
1350 Old Bayshore Highway, Suite 400, Burlingame, California, 94010
Website
www.inva.com
Telephone
1 650 2389600
No of Employees
159
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INVA (NASD)
Revenue (2024)
$411.3M
14.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1059.2%
(2024 vs 2023)
Market Cap*
$1.6B
Net Profit Margin (2024)
XYZ
911.0%
(2024 vs 2023)
* As of and is in US$
Innoviva Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Fluticasone Furoate | RELVAR |
| Vilanterol | BREO |
| Umeclidinium Bromide | ELLIPTA |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In June, the company received approval from the US FDA for priority review of Zoliflodacin, used to treat uncomplicated Gonorrhea. |
| 2025 | New Products/Services | In May, the company introduced ZEVTERA, an advanced-generation cephalosporin antibiotic to treat three types of bacterial infections. |
| 2024 | Contracts/Agreements | In December, the company's subsidiary Innoviva Specialty Therapeutics signed an agreement with Basilea Pharmaceutica Ltd, Allschwil for the commercialization of Zevtera (ceftobiprole). |
Competitor Comparison
| Key Parameters | Innoviva Inc | Merck & Co Inc | Pfizer Inc | AstraZeneca Plc | GSK plc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | United Kingdom |
| City | Burlingame | Rahway | New York City | Cambridge | London |
| State/Province | California | New Jersey | New York | Cambridgeshire | England |
| No. of Employees | 159 | 75,000 | 75,000 | 96,100 | 66,841 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark A. DiPaolo | Chairman | Executive Board | 2023 | 55 |
| Pavel Raifeld | Chief Executive Officer; Director | Executive Board | 2020 | 42 |
| Steve Basso | Chief Financial Officer | Senior Management | 2023 | 60 |
| Marianne Zhen | Chief Accounting Officer | Senior Management | 2018 | 57 |
| David Altarac, MD | Chief Medical Officer - Innoviva Specialty Therapeutics- Clinical, Regulatory, Safety, and Medical Affairs | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer